Understanding how HIV tests work, what the results mean, how to interpret viral load and CD4 count trends, and how to identify treatment failure is essential clinical knowledge for healthcare providers in sexual health, HIV medicine, primary care, obstetrics, and emergency medicine.
The HIV Diagnostic Window and Test Types
A critical concept in HIV testing is the diagnostic window period: the time between initial HIV infection and when a given test can reliably detect infection. Modern fourth-generation HIV tests (antigen/antibody combination assays) detect both HIV-1 p24 antigen (an early marker of viral replication, detectable 10 to 17 days after exposure) and HIV-1 and HIV-2 antibodies (detectable 3 to 4 weeks after exposure in most, with virtually all seroconverted by 45 days).
First generation antibody-only tests: detected antibodies only, with a window period of 3 months or longer. Now obsolete in most high-income countries.
Second and third generation assays: IgM and IgG antibody detection (third gen). Window period approximately 22 days.
Fourth generation (p24 Ag/Ab combined): detects p24 antigen and IgM/IgG antibodies simultaneously. Window period approximately 18 to 21 days. This is the standard recommended test in the UK, EU, and US.
HIV RNA PCR (viral load): detects HIV RNA directly, with a window period of approximately 10 to 12 days from exposure. Used when very early infection is suspected (acute HIV seroconversion illness) and the fourth-generation test is negative or indeterminate.
Point-of-care (POC) rapid HIV tests: finger-prick blood or oral fluid samples, result within 20 to 30 minutes. Used in community testing, emergency department settings, and resource-limited environments. POC tests are typically third-generation antibody tests (longer window) or fourth-generation combined tests depending on the product.
The Diagnostic Algorithm
UK (BHIVA) and WHO recommend a two-test confirmatory algorithm:
Step 1: Screening with a fourth-generation Ag/Ab assay. A reactive (positive) result on the screening assay is not diagnostic on its own: false positives occur (usually low-positive results from non-specific reactivity).
Step 2: Confirmatory testing with a second assay of different design (different antigen presentation or format) from the same or a different sample. A repeatedly reactive result on two different assays using different antigens/formats is a confirmed HIV-positive result.
For discordant results (reactive on one assay, non-reactive on a second): HIV RNA viral load testing is the definitive discriminator. A detectable HIV RNA with a high or very high viral load in the context of reactive screening confirms early HIV infection. An undetectable HIV RNA argues against active HIV infection and may reflect a false-positive screening result.
HIV type differentiation: confirmatory testing should distinguish HIV-1 from HIV-2. HIV-2 is less common (predominantly West Africa) but has natural resistance to some NNRTIs and requires different ART.
Baseline Assessment After HIV Diagnosis
When HIV infection is confirmed, a structured baseline assessment provides the clinical foundation for treatment decisions:
CD4 count (CD4+ T lymphocyte count): the most important marker of immune competence. Normal range: 500 to 1,200 cells/microlitre in adults. CD4 count below 200 cells/microlitre defines AIDS. Baseline CD4 count determines: urgency of ART initiation (all HIV-positive individuals should start ART as soon as possible regardless of CD4, but low CD4 requires even more urgent initiation), need for opportunistic infection prophylaxis (PCP prophylaxis below 200, MAC prophylaxis below 50 cells/microlitre), and baseline immune status for interpreting CD4 recovery on ART.
HIV viral load (plasma HIV RNA): quantified by PCR as copies/mL or log10 copies/mL. Baseline viral load is used to predict HIV progression risk and as the primary endpoint for ART response monitoring. After ART initiation, viral load should fall by 1 log10 within 1 month and become undetectable (below 50 copies/mL on most assays) within 3 to 6 months.
HIV drug resistance genotype: testing for transmitted drug resistance mutations (TDRM) before starting ART identifies primary resistance that affects ART choice. Prevalence of transmitted NNRTI resistance is approximately 8 to 10 per cent in many European cohorts.
Monitoring on Antiretroviral Therapy
The primary goal of ART is virological suppression: plasma HIV RNA below 50 copies/mL (or below 200 copies/mL depending on the assay and guideline). Virological suppression is associated with immune recovery (rising CD4 count), prevention of opportunistic infections, prevention of HIV transmission (Undetectable = Untransmittable, or U=U), and normal life expectancy.
Viral load monitoring schedule: at baseline, at ART initiation, at 1 and 3 months on ART (to confirm response), then every 3 to 6 months once suppressed and stable.
Virological failure: defined as confirmed HIV RNA above 50 to 200 copies/mL (depending on guideline) after 6 months of ART in a patient who was previously suppressed, or failure to achieve suppression by 6 months. Virological failure prompts: adherence assessment (most common cause), resistance genotyping (to identify accumulated resistance mutations), and ART regimen modification.
Blip: a single detectable viral load result (50 to 200 copies/mL) between periods of suppression, without confirmed virological failure. Blips are usually transient and not associated with resistance; repeat testing confirms return to suppression.
Frequently Asked Questions
What is the window period for HIV testing?
The window period is the time between HIV infection and when the test can reliably detect infection. Fourth-generation HIV tests (p24 antigen + antibody) have a window period of approximately 18 to 21 days. Most infections are detectable by 45 days with these tests. A negative result at 45 days after a single exposure effectively excludes HIV infection with high confidence.
What is the fourth-generation HIV test?
The fourth-generation HIV test is a combined assay that simultaneously detects HIV-1 p24 antigen (an early viral protein) and HIV-1 and HIV-2 antibodies. It is more sensitive for early HIV infection than antibody-only tests because p24 antigen appears 10 to 17 days after infection, before antibody seroconversion. It is the recommended screening test in the UK, EU, and US.
What is CD4 count and why does it matter in HIV?
The CD4 count measures the number of CD4-positive T helper lymphocytes per microlitre of blood. HIV preferentially infects and destroys CD4 cells. The CD4 count is the key marker of immune competence in HIV infection. A CD4 below 200 cells/microlitre defines AIDS and indicates high risk for opportunistic infections including PCP, cryptococcal meningitis, and CMV retinitis.
What is undetectable viral load?
An undetectable HIV viral load means the HIV RNA in blood is below the detection limit of the assay (typically below 50 copies/mL). On effective ART, virtually all patients achieve undetectable viral load within 6 months. Undetectable viral load means: the immune system is recovering, the risk of disease progression is very low, and (crucially) the person cannot sexually transmit HIV to an uninfected partner (U=U: Undetectable = Untransmittable, confirmed by PARTNER and HPTN 052 studies).
What is U=U?
Undetectable = Untransmittable (U=U) is the scientifically confirmed consensus that a person living with HIV who maintains an undetectable viral load on ART has effectively zero risk of sexually transmitting HIV to a partner. This is one of the most important public health messages in HIV, with profound implications for reducing stigma and for HIV prevention.
What is HIV drug resistance testing?
HIV drug resistance genotyping sequences the reverse transcriptase, protease, and integrase genes of the HIV genome and identifies mutations associated with reduced susceptibility to specific antiretroviral drugs. Resistance testing is performed before starting ART (to detect transmitted resistance) and at virological failure (to guide regimen modification). Resistance mutations accumulate in the viral quasispecies under drug selection pressure.
What is PrEP?
Pre-Exposure Prophylaxis (PrEP) is the use of antiretroviral drugs (typically tenofovir disoproxil fumarate/emtricitabine) by HIV-negative individuals before and after potential HIV exposures to prevent infection. PrEP reduces HIV acquisition risk by more than 99 per cent when taken as prescribed. PrEP requires regular HIV testing (to confirm HIV-negative status before continuing), kidney function monitoring (TDF can cause nephrotoxicity), and STI screening.
What is PEP?
Post-Exposure Prophylaxis (PEP) is a 28-day course of combination antiretroviral therapy taken after a potential HIV exposure (unprotected sex, needlestick injury, sexual assault) to prevent establishment of HIV infection. PEP must be started within 72 hours of exposure (ideally within 24 hours) and is most effective when started promptly. HIV testing is performed before starting PEP and at 45 to 90 days after the potential exposure.
What is the significance of baseline HIV resistance testing?
Transmitted drug resistance (primary resistance) is present in 8 to 15 per cent of newly diagnosed HIV patients in Europe. Resistance to efavirenz (an NNRTI) is the most common type of transmitted resistance. Baseline resistance genotyping ensures that the initial ART regimen is fully active against the patient's viral strain, avoiding early virological failure from a resistance mismatch.
What happens to CD4 count on effective ART?
On effective ART that achieves undetectable viral load, CD4 count typically rises by 100 to 150 cells/microlitre per year in the first 2 years, often plateauing at 500 to 800 cells/microlitre or higher. Patients who start ART at very low CD4 counts may not fully recover to normal ranges. CD4 recovery correlates with reduction in opportunistic infection risk: PCP prophylaxis can be safely stopped when CD4 rises above 200 for at least 3 months.